3200% premium for innovation!!

April 2012

Discussion posted on Pharmaceutical Discussion Group on Linkedin

http://www.linkedin.com/groups/PhRMA-says-price-as-trigger-38263.S.105200659?qid=8b279aac-88f8-4538-b788-061d5b62bd1d&trk=group_search_item_list-0-b-cmr&goback=%2Egmr_38263

PhRMA says price as trigger for compulsory license is not provided for in TRIPS - wonder if TRIPS provides for 3200% premium for innovation?

Reference article:

PhRMA’s Special 301 Comments on Indian Compulsory Licensing...infojustice.org

PhRMA’s Special 301 comments to the U.S. Trade Representative include a section on the compulsory licensing provisions in India’s Patents Act.  PhRMA recommends that “India should ensure that the CL provisions comply with TRIPS...